The company has secured 506 marketing approvals for its oncology products across 76 countries.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
UTD2 is the world's first oral epothilone microtubule inhibitor
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Subscribe To Our Newsletter & Stay Updated
